Tirzepatide is a novel synthetic peptide acting as a dual agonist at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Research interest has grown significantly due to its unique dual-receptor mechanism, which distinguishes it from single-receptor GLP-1 agonists in metabolic pathway studies.

Preclinical and clinical investigations have examined its effects on insulin secretion dynamics, glucagon suppression, gastric motility, and energy expenditure in research models. Its structural design as a single molecule targeting two incretin receptors simultaneously makes it a compound of considerable interest in peptide pharmacology research.

Each vial is supplied as lyophilized powder, third-party tested via LC-MS analysis, and ships with a Certificate of Analysis confirming identity and purity.

Specifications: CAS Number: 2023788-19-2 | Molecular Weight: 4,813.5 Da | Purity: >99% | Form: Lyophilized Powder | Storage: -20°C long-term / 4°C short-term

⚠️ For Research Use Only. Not intended for human consumption, medical, diagnostic, or therapeutic purposes. For use by licensed researchers only in controlled laboratory settings.